Illness Forces Fidji Simo Out of OpenAI’s No. 2 Role as Greg Brockman Tightens Grip on Product Power

• Early 2025–2024: Simo’s fast rise at OpenAI
• April 2026: Health crisis and medical leave
• May 2026: Reorganization around AI agents
• July 9, 2026: Simo steps down, Altman reacts
• July 11, 2026: Brockman’s product power becomes permanent

Illness Forces Fidji Simo Out of OpenAI’s No. 2 Role as Greg Brockman Tightens Grip on Product Power
OpenAI is undergoing a quiet but consequential power shift, as chronic illness pushes Fidji Simo out of the company’s No. 2 role just as co‑founder Greg Brockman cements control over product strategy.

§Early 2025–2024: Simo’s fast rise at OpenAI

Fidji Simo joined OpenAI’s board in 2024, then in May 2025 became CEO of Applications, a newly created role that consolidated business and product operations under her and reported directly to CEO Sam Altman. Her mandate was to turn cutting‑edge AI research into a durable business, including consumer growth and enterprise products, at a time when OpenAI was pouring tens of billions into its technology while trailing Anthropic for some key customers.

§April 2026: Health crisis and medical leave

In April 2026, Simo disclosed to staff that she was taking medical leave after a relapse of a neuroimmune condition. She later described the episode as “a severe exacerbation of a chronic illness I’ve lived with for seven years,” noting that her road to recovery would be “much longer and more complex” than she expected and that she needed to focus on it fully. She has been diagnosed with postural tachycardia syndrome (POTS), a “disabling disease that still has no cure.”

Her April memo coincided with other senior changes: COO Brad Lightcap moved to “special projects,” and CMO Kate Rouch stepped back to focus on cancer recovery. During Simo’s leave, president Greg Brockman temporarily took charge of product and OpenAI’s “super app” efforts.

§May 2026: Reorganization around AI agents

About a month later, OpenAI launched a major reorganization led by Brockman. He formally assumed control of product strategy and “scaling,” overseeing four pillars: core product and platform; critical enterprise industries; consumer; and core infrastructure, ads, data science, and growth. In a memo, Brockman argued the shift would help OpenAI prioritize its AI agent ambitions by investing in “a single agentic platform” and merging ChatGPT and Codex “into one unified agentic experience for all.”

§July 9, 2026: Simo steps down, Altman reacts

On July 9, Simo told staff and then the public that she would leave her full‑time role and transition to a part‑time advisory position, citing the prolonged and debilitating nature of her illness. Multiple outlets reported that OpenAI’s No. 2 executive was stepping down just as the company eyes a possible IPO and faces intense competition from Anthropic in the enterprise market.

Altman publicly responded on X, writing: “i am really sad about this and very grateful for all fidji has done for openai … we all wish her the best for a speedy recovery. this sucks.”

§July 11, 2026: Brockman’s product power becomes permanent

By July 11, reports confirmed that Brockman, who had stepped in during Simo’s leave, would “keep heading up product at the company” on a permanent basis. Commentators framed the move as a consolidation of power under the co‑founder ahead of a potential IPO.

From Simo’s perspective, the decision is rooted in health and personal limits; from OpenAI’s, it accelerates a pivot to a unified agent platform under Brockman’s control; and for investors and rivals, it sharpens questions about succession, governance, and focus at a company racing to commercialize artificial general intelligence.

Continue reading https://foxvector.com/stories/019f675c-e3d8-31b6-7031-07668b9a19bc